Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Google became the gateway to the internet by perfecting its search engine. For two decades, it surfaced 10 blue links that ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Sen. Susan Collins asked Secretary of State Marco Rubio about the Trump administration's cutbacks to global health initiatives during Rubio's appearance before a Senate committee Tuesday. "I am ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

Experts say the test could dramatically improve access to earlier, more accurate diagnoses, particularly for older Americans ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...